Publications by authors named "Mark Knafl"

Claim this Profile
E
Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: A COVID-era ILROG collaborative report.
Jillian R Gunther, Joanna C Yang, Carla Hajj, Andrea K Ng, Jessica L Brady, Mark Knafl

Radiother Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer Testis Antigen Expression Correlates With Immune Activation and Survival in Small Bowel Neuroendocrine Tumors.
Reed I Ayabe, Y David Seo, Brenda Melendez, Brittany C Fields, Laurence P Diggs, Mark Knafl

JCO Precis Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal.
Van K Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Mark Knafl

Clin Cancer Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy.
James P Long, Rishab Prakash, Paul Edelkamp, Mark Knafl, Anath C Lionel

JAMA Netw Open· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma.
Mahmoud Yousef, Abdelrahman Yousef, Mark W Hurd, Ashwathy Pillai, Saikat Chowdhury, Mark Knafl

J Hematol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial.
Shiao-Pei Weathers, Xiqi Li, Haifeng Zhu, Ashish V Damania, Mark Knafl

Nat Commun· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival.
Mahmoud Yousef, Abdelrahman Yousef, Saikat Chowdhury, Mohammad M Fanaeian, Mark Knafl

JAMA Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer.
Xiaoping Wang, Li Zhao, Xingzhi Song, Xiaogang Wu, Savitri Krishnamurthy, Mark Knafl

NPJ Precis Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma.
Nicholas J Hornstein, Mohammad A Zeineddine, Betul B Gunes, Andrew J Pellatt, Mark Knafl

Cancer Res Commun· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automated, High-Throughput Platform to Generate a High-Reliability, Comprehensive Rectal Cancer Database.
Neal Bhutiani, Mahmoud M G Yousef, Abdelrahman Yousef, Mohammad Zeineddine, Mark Knafl

JCO Clin Cancer Inform· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma.
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, Kawther Abdilleh, Mark Knafl

NPJ Precis Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma.
Abdelrahman Yousef, Mahmoud Yousef, Mohammad A Zeineddine, Aditya More, Mohammad Fanaeian, Mark Knafl

JAMA Netw Open· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Clinical Significance of CEA, CA19-9, and CA125 in Management of Appendiceal Adenocarcinoma.
Abdelrahman Yousef, Mahmoud Yousef, Mohammad Zeineddine, Aditya More, Saikat Chowdhury, Mark Knafl

medRxiv· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma.
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, Kawther Abdilleh, Mark Knafl

Res Sq· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19.
Dereddi Raja Reddy, John A Cuenca, Joshua Botdorf, Mayoora Muthu, Ankit Hanmandlu, Mark Knafl

Mayo Clin Proc· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine Learning Models Using Routinely Collected Clinical Data Offer Robust and Interpretable Predictions of 90-Day Unplanned Acute Care Use for Cancer Immunotherapy Patients.
Sheng-Chieh Lu, Mark Knafl, Anastasia Turin, Anaeze C Offodile, Vinod Ravi

JCO Clin Cancer Inform· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma.
Ethan P Damron, Muzaffar H Qazilbash, Penny Q Fang, Susan Y Wu, Bouthaina S Dabaja, Mark K Knafl

Transplant Cell Ther· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial.
Daniel M Halperin, Suyu Liu, Arvind Dasari, David Fogelman, Priya Bhosale, Mark Knafl

JAMA Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.
Kanwal Raghav, Suyu Liu, Michael J Overman, Anneleis F Willett, Mark Knafl

Cancer Discov· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis